ANSTO to manufacture skin cancer treatment
Nuclear science and technology organisation ANSTO has been licensed as the Australian manufacturing partner of a new non-invasive treatment for non-melanoma skin cancer (NMSC). Radioisotope developer OncoBeta and ANSTO will establish local manufacturing of the company’s epidermal radioisotope therapy, Rhenium-SCT (Skin Cancer Therapy) for the treatment of non-melanoma skin cancer. ANSTO operates the OPAL nuclear…
Details










